
News briefing: Cosentyx shows early positive signs in psoriatic arthritis; Pfizer's PhIIb for cardio drug triggers $75M milestone
Novartis’ blockbuster Cosentyx is seeking approval in another indication, and the company reported positive early Phase IIIb results Thursday.
Looking to reduce joint lining inflammation in psoriatic arthritis, Cosentyx saw benefits against placebo after 12 weeks. Though Novartis didn’t provide any numbers in this early look, the company said the drug showed “significant benefit” on its way to meeting the primary endpoint.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.